SSG
LRMR icon

Summit Securities Group’s Larimar Therapeutics LRMR Stock Holding History

Summit Securities Group’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-794
Closed -$3.57K – 1284
2026
Q1 		$3.57K Buy
+794
New +$3.17K ﹤0.01% 859

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Summit Securities Group's LRMR Position: Q2 2026 in Review

Summit Securities Group sold out of Larimar Therapeutics (LRMR) in Q2 2026, closing a stake of 794 shares — an estimated $3.57K sold.

Summit Securities Group first reported a position in LRMR in Q1 2026 and held it in 1 quarter. The position peaked at $3.57K in Q1 2026. 162 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Summit Securities Group reported no remaining Larimar Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Summit Securities Group sold 794 Larimar Therapeutics shares in Q2 2026, an estimated $3.57K.
  • Summit Securities Group first reported a position in Larimar Therapeutics in Q1 2026 and held it in 1 quarter.
  • Summit Securities Group's Larimar Therapeutics position peaked at $3.57K in Q1 2026.
  • 162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Summit Securities Group's 13F filing for Q2 2026, filed 3 Aug 2026.